Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel.
Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel.
J Cancer Res Clin Oncol. 2019 Mar;145(3):609-613. doi: 10.1007/s00432-018-2812-4. Epub 2018 Dec 6.
The botanical formula LCS101 has been shown in clinical research to reduce chemotherapy-induced toxicities. In pre-clinical research, the formula demonstrated selective anti-cancer effects, in part as a result of radical oxygen species (ROS) activity of the botanical components. The present study examined the interaction between LCS101 and radiation therapy on cancer cell lines.
Incremental doses of LCS101 were added to breast adenocarcinoma (MCF7), prostate (DU145), transitional cell bladder carcinoma (T24), pancreatic epithelioid carcinoma (PANC-1), and osteosarcoma (U20S) cell lines 4 h after single-dose irradiation (range 0.5-4 Gy). Cell viability was tested using sulforhodamine B (SRB) assay after 1 week, with ROS activity examined using 1 mM of the ROS scavenger sodium pyruvate (ROS scavenger), testing cell viability with an SRB assay.
The addition of LCS101 to MCF7 (breast) and DU-145 (prostate) cancer cell lines resulted in a dose-dependent increase in the antiproliferative effects of radiation treatment. The addition of pyruvate inhibited radiation-induced cell death in all of the cell lines treated with LCS101.
The addition of the botanical formula LCS101 to irradiated cancer cells results in an apparent additive effect, most likely through a ROS-mediated mechanism. These findings support the use of LCS101 by patients undergoing radiation therapy, for both its clinical as well as anti-cancer effects.
临床研究表明，植物配方 LCS101 可降低化疗引起的毒性。在临床前研究中，该配方表现出选择性的抗癌作用，部分原因是植物成分的活性氧（ROS）。本研究探讨了 LCS101 与放射疗法对癌细胞系的相互作用。
在单次照射后 4 小时（范围 0.5-4Gy），将递增剂量的 LCS101 添加到乳腺腺癌（MCF7）、前列腺（DU145）、移行细胞膀胱癌（T24）、胰腺上皮样癌（PANC-1）和骨肉瘤（U20S）细胞系中。1 周后用磺酰罗丹明 B（SRB）测定法检测细胞活力，用 1mMROS 清除剂丙酮酸（ROS 清除剂）检测 ROS 活性，用 SRB 测定法检测细胞活力。
LCS101 与 MCF7（乳腺）和 DU-145（前列腺）癌细胞系的联合使用导致放射治疗的抗增殖作用呈剂量依赖性增加。在所有用 LCS101 处理的细胞系中，添加丙酮酸抑制了放射诱导的细胞死亡。
向辐照癌细胞中添加植物配方 LCS101 会产生明显的相加作用，很可能通过 ROS 介导的机制。这些发现支持将 LCS101 用于接受放射治疗的患者，以获得其临床和抗癌作用。
